TRCT
NKGN

Tower Research Capital (TRC)’s NKGen Biotech, Inc. Common Stock NKGN Stock Holding History

Tower Research Capital (TRC)’s Portfolio NKGN Stock Details NKGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,782
Closed -$1.82K – 5997
2024
Q4 		$1.82K Sell
2,782
-8,953
-76% -$3.65K ﹤0.01% 4952
2024
Q3 		$4.44K Buy
11,735
+8,850
+307% +$7.85K ﹤0.01% 4542
2024
Q2 		$3.66K Sell
2,885
-939
-25% -$1.31K ﹤0.01% 4865
2024
Q1 		$7.23K Buy
+3,824
New +$7.34K ﹤0.01% 4239

Other funds holding NKGN

DC
Diametric Capital Boston, Massachusetts $385M AUM 31.69% 1-Year Est. Return
UOC
University of Chicago Chicago, Illinois $323M AUM 14.1% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return

Tower Research Capital (TRC)'s NKGN Position: Q1 2025 in Review

Tower Research Capital (TRC) sold out of NKGen Biotech, Inc. Common Stock (NKGN) in Q1 2025, closing a stake of 2,782 shares — an estimated $1.82K sold.

Tower Research Capital (TRC) first reported a position in NKGN in Q1 2024 and held it in 4 quarters. The position peaked at $7.23K in Q1 2024. 3 funds tracked by Wall St. Rank hold NKGN as of Q1 2025.

  • Tower Research Capital (TRC) reported no remaining NKGen Biotech, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 2,782 NKGen Biotech, Inc. Common Stock shares in Q1 2025, an estimated $1.82K.
  • Tower Research Capital (TRC) first reported a position in NKGen Biotech, Inc. Common Stock in Q1 2024 and held it in 4 quarters.
  • Tower Research Capital (TRC)'s NKGen Biotech, Inc. Common Stock position peaked at $7.23K in Q1 2024.
  • 3 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Common Stock as of Q1 2025.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2025, filed 15 May 2025.